Roivant Sciences Ltd. is a biopharmaceutical company that develops and commercializes medicines through nimble subsidiaries called 'Vants.' Its pipeline includes brepocitinib (TYK2/JAK1 inhibitor) for dermatomyositis, uveitis, and cutaneous sarcoidosis; IMVT-1402 and batoclimab (anti-FcRn antibodies) for IgG-mediated autoimmune diseases; and mosliciguat (inhaled sGC activator) for pulmonary hypertension. Since 2014, Roivant has received 8 FDA approvals and completed 12 large registrational Phase 3 studies. The company also pursues patent infringement litigation against Moderna and Pfizer/BioNTech.
expected 2026-12-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-05-29 | 2025-03-31 | 0001140361-25-020715 | EDGAR | 145K words |
| 2024-05-30 | 2024-03-31 | 0001140361-24-028145 | EDGAR | 142K words |
| 2023-06-28 | 2023-03-31 | 0001140361-23-031798 | EDGAR | 154K words |
| 2022-06-28 | 2022-03-31 | 0001193125-22-183362 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001635088-26-000090 | EDGAR | 25K words |
| 2026-02-06 | 2025-12-31 | 0001635088-26-000011 | EDGAR | 86K words |
| 2025-11-10 | 2025-09-30 | 0001635088-25-000016 | EDGAR | 84K words |
| 2025-08-11 | 2025-06-30 | 0001140361-25-030001 | EDGAR | 88K words |
| 2025-02-10 | 2024-12-31 | 0001140361-25-003661 | EDGAR | 89K words |
| 2024-11-12 | 2024-09-30 | 0001140361-24-046019 | EDGAR | 88K words |
| 2024-08-09 | 2024-06-30 | 0001140361-24-036642 | EDGAR | 86K words |
| 2024-02-13 | 2023-12-31 | 0001140361-24-007260 | EDGAR | 93K words |
| 2023-11-13 | 2023-09-30 | 0001140361-23-052721 | EDGAR | 90K words |
| 2023-08-14 | 2023-06-30 | 0001140361-23-039406 | EDGAR | 87K words |
| 2023-02-13 | 2022-12-31 | 0001140361-23-006180 | EDGAR | 96K words |
| 2022-11-14 | 2022-09-30 | 0001140361-22-041175 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-18 | 0001635088-26-000095 | EDGAR | 1K words |
| 2026-09-08 | 0001140361-26-035859 | EDGAR | 2K words |
| 2026-08-28 | 0001140361-26-034854 | EDGAR | 4K words |
| 2026-08-27 | 0001140361-26-034735 | EDGAR | 3K words |
| 2026-08-06 | 0001635088-26-000088 | EDGAR | 3K words |
| 2026-04-02 | 0001140361-26-012885 | EDGAR | 1K words |
| 2026-03-03 | 0001140361-26-007548 | EDGAR | 2K words |
| 2026-03-03 | 0001140361-26-007447 | EDGAR | 1K words |
| 2026-02-06 | 0001635088-26-000009 | EDGAR | 5K words |
| 2025-12-11 | 0001140361-25-045204 | EDGAR | 17K words |
118 total filings indexed. 92 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001635088 |
| Ticker | ROIV |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | D0 |
| Website | https://www.roivant.com |
| Listed | 2021-10-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ROIV (~200 tokens, structured JSON with cryptographic provenance)